Vitrolife Acquires Igenomix from EQT and Charme for EUR 1.25 billion
July 8, 2021
Vitrolife AB has agreed to acquire Igenomix from EQT Private Equity and Charme Capital Partners for an enterprise value of EUR 1.25 billion. The deal combines Vitrolife's IVF product business with Igenomix's reproductive genetic testing capabilities to create a global leader in reproductive health; sellers will retain minority stakes in Vitrolife and the transaction will be funded with cash and newly issued shares.
- Buyers
- Vitrolife AB
- Targets
- Igenomix
- Sellers
- EQT Private Equity, Charme Capital Partners
- Industry
- Healthcare Services
- Location
- Valencian Community, Spain
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
EQT Acquires Igenomix from Charme Capital; Management and Charme Reinvest
June 18, 2019
Biotechnology
EQT VIII (EQT Partners) has agreed to acquire a majority stake in Igenomix, a Valencia-headquartered leader in reproductive genetic services, from Charme Capital, management and other minority owners. Charme Capital and the Igenomix management team will reinvest significant minority stakes, and EQT will support the company's continued international expansion and R&D-led growth.
-
Twist Bioscience Acquires iGenomX
June 30, 2021
Biotechnology
Twist Bioscience acquired iGenomX, a developer of high-throughput multiplex NGS library preparation tools, to expand its NGS workflow capabilities and accelerate customer conversion from microarray genotyping to sequencing-based genotyping. The deal consideration was $35 million (combination of cash and Twist stock, plus up to $5 million contingent stock), and Twist expects modest near-term financial impact with incremental revenue from the acquired business in fiscal 2023.
-
Igenomix Acquires Access Genomics Canada from Persistence Capital Partners
December 14, 2020
Biotechnology
Igenomix, a Spanish reproductive-genetics company, acquired Toronto-based laboratory Access Genomics (Access Genomics Canada) from Persistence Capital Partners on December 14, 2020. The acquisition expands Igenomix’s presence in North America and strengthens its ability to serve fertility clinics in the Toronto area.
-
Charles River Laboratories Acquires Vigene Biosciences
May 17, 2021
Biotechnology
Charles River Laboratories agreed to acquire Vigene Biosciences, a Rockville, Maryland-based gene therapy CDMO, for $292.5 million in cash plus up to $57.5 million in contingent payments. The acquisition expands Charles River's cell and gene therapy contract development and manufacturing capabilities—adding CGMP viral vector and plasmid DNA production—and is expected to close in early Q3 2021.
-
In Vitro Sciences (Sverica) Partners with InVia Fertility Specialists
August 26, 2020
Healthcare Services
In Via Fertility Specialists has entered a partnership with In Vitro Sciences, a portfolio company of Sverica Capital Management, with Dresner Partners advising InVia on the transaction. InVia — a four-location fertility clinic group in the Chicagoland area with an on-site embryology lab and three reproductive endocrinologists — will gain strategic, operational and financial resources to support growth and enhance patient care.
-
OmniActive Health Technologies Acquires ENovate Biolife
November 4, 2024
Food & Beverage
OmniActive Health Technologies has acquired ENovate Biolife to expand its portfolio of clinically validated botanical and specialty active ingredients for dietary supplements, functional foods and sports nutrition. The acquisition strengthens OmniActive's R&D, clinical and commercial capabilities and aims to accelerate global distribution of ENovate's ingredients such as Muvz, RedNite and Oxyjun.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.